Your cart is currently empty!
Innovators & Researchers
80% of CGT discoveries never reach the clinic,
not because the science fail, but because the translation fails
You’ve published and got promising in vivo data,
but when you talk to investors or CDMOs, you hear questions
about CMC strategy, IND toxicology plan, and quality team.
You’re stuck in the academic-to-seed gap, and we built our firm to close it.
Three services, one path to IND
Translation Assessment
A roadmap from the bench to IND
An evaluation of your program’s translational ability, a Go/No-Go recommendation, and an IND roadmap
- Regulatory pathway
- Manufacturing feasibility
- Investor readiness
Seed Strategy
From assessment to investment-ready
A development plan that makes your program a seed‑stage asset that investors would fund
- Preclinical development
- CMC Strategy
- Quality roadmap
Operational Bridge
From planning to GMP batch
Execution support that fills your team’s gaps. We go beyond advisory to manage, build, and prepare
- CDMO project management
- Quality systems
- Team support
All these services are available to you in tailored packages, based on the technical needs. View the details in our packages page or talk our expert now!